CAS NO: | 1051375-19-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailableHIV integrasestrand transferinhibitor with anIC50of 2.7 nM forHIV-1integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibitsHIV-1viral replication with an IC50of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against theHIV-1Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2]. | ||||||||||||||||
IC50& Target | IC50: 2.7 nM (HIV-1 integrase)[1] | ||||||||||||||||
体外研究 (In Vitro) | The EC50of Dolutegravir (S/GSK1349572) against HIV-1 is 0.51 nM in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the PHIV assay, which uses a pseudotyped self-inactivating virus. The 50% cytotoxic concentrations (CC50) for Dolutegravir in proliferating IM-9, U-937, MT-4, and Molt-4 cells are 4.8, 7.0, 14, and 15 μM, respectively. In unstimulated and stimulated PBMCs, the CC50are 189 μM and 52 μM, respectively. Based on the EC50of Dolutegravir against HIV-1 in PBMCs (i.e., 0.51 nM), this translates to a cell-based therapeutic index of at least 9,400[1]. | ||||||||||||||||
体内研究 (In Vivo) | Following a single intravenous (IV) administration of Dolutegravir, the plasma clearance is low in rats (0.23 mL/min/kg) and monkeys (2.12 mL/min/kg). The half-lives in the rat and monkey are similar, approximately 6 h, and the steady-state volume of distribution (VSS) is low. Following oral administration, Dolutegravir is rapidly absorbed with a high oral bioavailability when administered as a solution to fasted male rats and a single monkey (75.6 and 87.0%, respectively). Dolutegravir exposure (Cmaxand AUC) increased with increasing dose following oral administration of a suspension to non-fasted rats up to 250 mg/kg and non-fasted monkeys up to 50 mg/kg, although the increase is less than proportional[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 441.36 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H18F2N3NaO5 | ||||||||||||||||
CAS 号 | 1051375-19-9 | ||||||||||||||||
中文名称 | 度鲁特韦钠盐 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 4.5 mg/mL(10.20 mM) H2O :< 0.1 mg/mL(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |